XML 17 R8.htm IDEA: XBRL DOCUMENT v3.23.2
Insider Trading Arrangements
 6 Months Ended
Jun. 30, 2023
shares
Trading Arrangements, by Individual  
Material Terms of Trading Arrangement

On May 10, 2023, a Rule 10b5-1 trading arrangement adopted on May 10, 2022 by Stephen Pakola, M.D., our EVP, Chief Medical Officer, which was intended to satisfy the affirmative defense of Rule 10b5-1(c) (the "Rule 10b5-1 Plan"), expired pursuant to its terms. In the aggregate 3,138 shares of our common stock were sold under the Rule 10b5-1 Plan prior to its expiration.

Other than as described above, during the three months ended June 30, 2023, none of our directors or Section 16 reporting officers adopted or terminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of the SEC's Regulation S-K).
Stephen Pakola [Member]  
Trading Arrangements, by Individual  
Name Stephen Pakola
Title M.D., our EVP, Chief Medical Officer
Rule 10b5-1 Arrangement Adopted true
Adoption Date May 10, 2022
Aggregate Available 3,138,000
Directors or Section 16 Reporting Officers [Member]  
Trading Arrangements, by Individual  
Title directors or Section 16 reporting officers
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false